CN104587034B - 一种药物组合物在用于制备治疗口腔溃疡的新用途 - Google Patents
一种药物组合物在用于制备治疗口腔溃疡的新用途 Download PDFInfo
- Publication number
- CN104587034B CN104587034B CN201510094348.6A CN201510094348A CN104587034B CN 104587034 B CN104587034 B CN 104587034B CN 201510094348 A CN201510094348 A CN 201510094348A CN 104587034 B CN104587034 B CN 104587034B
- Authority
- CN
- China
- Prior art keywords
- ulcer
- oral ulcer
- group
- mel
- herba houttuyniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 7
- 208000002399 aphthous stomatitis Diseases 0.000 title abstract description 35
- 208000007117 Oral Ulcer Diseases 0.000 title abstract description 32
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims description 31
- 210000000582 semen Anatomy 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 2
- 235000012907 honey Nutrition 0.000 abstract description 2
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 21
- 231100000397 ulcer Toxicity 0.000 description 21
- 229940079593 drug Drugs 0.000 description 14
- 241000700199 Cavia porcellus Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 206010030113 Oedema Diseases 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- 241000256844 Apis mellifera Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 244000293323 Cosmos caudatus Species 0.000 description 2
- 235000005956 Cosmos caudatus Nutrition 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940097275 indigo Drugs 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000256846 Apis cerana Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 241000959626 Calvatia Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 235000014552 Cassia tora Nutrition 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 235000008597 Diospyros kaki Nutrition 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241001627955 Tetraodon lineatus Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种药物组合物在用于制备治疗口腔溃疡的新用途,该药物组合物包含西洋参5‑20g,鱼腥草7‑25g,决明子5‑18g,蜂蜜7‑25g。
Description
技术领域
本发明涉及一种药物组合物在用于治疗口腔溃疡的新用途,属于医药技术领域。
背景技术
口腔溃疡是一种常见的口腔疾患,中医称之为口疮,是一种以口腔黏膜反复发作的疼痛性溃疡为特点的慢性炎症,表现为单个或多个的浅表性溃疡,其患病率高,主要表现为唇、颊、舌、口底、软腭单发或多发孤立的圆形或椭圆形浅表溃疡,边缘整齐有明显红晕,基底灰白色或灰黄色,伴剧烈灼痛。
口腔溃疡的发病机制复杂,有明显的个体差异,反复发作严重影响患者的身心健康。多数学者认为,本病的发生与感染、免疫功能异常、维生素及微量元素缺乏等有关,临床亦针对上述因素进行治疗;中医理论认为,心脾积热、阴虚火旺及气血亏虚是形成口疮的主要病机。
目前临床上无根治口腔溃疡的特效方法。国内外已有多种不同治疗口腔溃疡的方法,目前以局部用药为主,重型者结合全身用药。西医治疗口腔溃疡主要使用抗生素类消炎药,服用抗生素类消炎药对人体有毒副作用,特别是对反复发生口腔溃疡的人来说,长期服用抗生素,会导致菌群失调,引起其他疾病用抗生素类消炎药,有可能使机体免疫力下降,从而引发其它疾病。中药主要运用清热解毒的散剂进行敷溃疡面以达到治疗效果,但由于药味道苦涩,且药物繁多复杂,并不能为大众接受。
现有专利技术中提供的技术方案成分比较复杂,如CN201010600379公开了一种治疗口腔溃疡的中药散剂,其原料药为:青黛8~12g、硼砂(煅)8~12g、柿霜16~24g、象牙屑(焙)8~12g、珍珠3~6g、玄明粉8~12g、人指甲(焙)2.4~3.2g、血蝎3~5g、孩儿茶8~10g、马勃1.6~2.4g、露蜂房(炒)2.4~4.2g、枯矾3~5g、西瓜霜8~13g、细辛0.4~0.9g、薄荷脑0.3~0.8g、蛇蜕(炙)1.6~2.4g、象皮(焙)3~9g、甘草6~10g、牛黄0.6~1g、甜菊素0.6~1g、冰片0.15~0.3g。
CN201210424704公开了一种治疗口腔溃疡的外用药:黄连30-50、黄柏30-50、乳香14-26、没药14-26、肉桂14-26、炉甘石30-50、血力花30-50、冰片14-26、珍珠14-26、五花龙骨14-26、五倍子60-100、月石90-150、甘草30-50、青黛30-50。以上所述技术方案的特点是所含成分复杂,不利于药物组合物的调配及使用。
因此,提供一种组方简单、药材资源易得、药性平和、无毒副作用、味道能被广大病患所接受,治疗口腔溃疡疗效好的中药制剂,是目前需要解决的技术问题。
发明内容
一种药物组合物在用于制备治疗口腔溃疡的新用途,所述药物组合物包含西洋参、鱼腥草、决明子、蜂蜜。
优选地,所述药物组合物包括:西洋参5-20g,鱼腥草7-25g,决明子5-18g,蜂蜜7-25g。
进一步优选地,所述药物组合物包括:西洋参8-18g,鱼腥草10-25g,决明子8-18g,蜂蜜8-23g。
进一步优选地,所述药物组合物包括:西洋参8g,鱼腥草20g,决明子15g,蜂蜜10g。
本发明提供的组方简单,药材资源易得,药性平和,味道能被广大病患所接受,且能有效促进溃疡面的愈合,减轻疼痛及其他症状,天然,副作用少。
西洋参(别名洋参、西参、西洋人参、花旗参)为五加科植物西洋参PanaxquinquefoliumL.的干燥根。性味甘、微苦、凉;归心、肺、肾经。
有补气养阴,清热生津之功效,用于气虚阴亏、内热、咳喘痰血、虚热烦倦、消渴、口燥咽干。
决明子为豆科植物决明Cassia obtusifolia L.或小决明Cassia toraL.的干燥成熟种子。性味咸苦、平凉、无毒。归肝、胆、肾经。具有祛风清热,解毒利湿之功效。用于风热感冒、流感、急性结膜炎、湿热黄疸、急性慢肾炎、带下、瘰疬、疮痈疖肿、乳腺炎。
鱼腥草为三白草科植物蕺菜Houttuynia cordata Thunb.的干燥地上部分。性味辛、寒。功效清热解毒,利尿消肿,用于治疗肺炎、肺脓疡、热痢、疟疾、水肿、淋病、白带、痈肿、痔疮、脱肛、湿疹、秃疮、疥癣。
蜂蜜为蜜蜂科昆虫中华蜜蜂Apis cerana Fabricius或意大利蜂APismelliferaLinnaeus所酿的蜜。性味甘、性平。归脾、胃、肺、大肠经。具有调补脾胃,缓急止痛,润肺止咳,润肠通便,润肤生肌,解毒之功效。主脘腹虚痛,肺燥咳嗽,肠燥便秘,目赤,口疮,溃疡不敛,风疹瘙痒,水火烫伤,手足(皸)裂。
该药物组合物选择西洋参补气养阴,清热生津为君药;决明子祛风清热,解毒利湿为臣药;鱼腥草清热解毒,利尿消肿为佐药;蜂蜜为使药。诸药合用发挥出养阴清热解毒的功效,根源上解除病因,从而根除病症。目前由西洋参、鱼腥草、决明子、蜂蜜组成的药物组合物在治疗口腔溃疡方面尚无报道。本发明是在通过动物实验的基础上,验证该药物组合物的新用途。
本发明是通过建立石碳酸烧灼颊黏膜制备豚鼠口腔溃疡模型,围绕药物组合物高中低剂量组、模型组以及冰硼散组对豚鼠口腔溃疡模型溃疡面积的影响,观察各个组别局部出现的显著病理变化以及口腔溃疡局部病理损伤的改变等,分析药物组合物高中低剂量组对口腔溃疡的疗效。
研究结果表明:药物组合物的高中低剂量组,可显著缩小口腔溃疡面积,明显减轻溃疡局部症状,能显著减轻豚鼠口腔溃疡局部病理改变。高剂量组的疗效优于中剂量,中剂量的疗效优于低剂量组。
具体实施方式
下面结合具体实施方式,对本发明的权利要求作进一步的详细说明,但不构成对本发明的任何限制,任何在本发明权利要求范围内所做的有限的修改,仍在本发明的权利要求保护范围之内。
实施例1
组合物:西洋参5g,鱼腥草7g,决明子5g,蜂蜜(含水量30%)10g。
a)西洋参5g磨粉过120目,得粉末1,备用。
b)鱼腥草7g、决明子5g加入500ml清水,浸泡20分钟后,煎煮1小时,得100ml汤剂,取上清液,过滤,得滤液2,备用。
c)粉末1加入滤液2,混合搅拌,文火蒸发水分,得膏状混合物,加入蜂蜜10g,搅拌均匀,即可。
实施例2
组合物:西洋参8g,鱼腥草20g,决明子15g,蜂蜜(含水量30%)10g
a)西洋参8g磨粉,过120目,得粉末1,备用。
b)鱼腥草20g、决明子15g加入1500ml清水,浸泡20分钟后,煎煮1.5小时,得100ml汤剂,取上清液,过滤,得滤液2,备用。
粉末1加入滤液2,混合搅拌,文火蒸发水分,得膏状混合物,加入蜂蜜10g,搅拌均匀,即可。
实施例3
组合物:西洋参20g,鱼腥草25g,决明子18g,蜂蜜(含水量30%)10g。
a)西洋参20g磨粉,过120目,得粉末1,备用。
b)鱼腥草25g、决明子18g加入1500ml清水,浸泡20分钟后,煎煮1.5小时,得100ml汤剂,取上清液,过滤,得滤液2,备用。
c)粉末1加入滤液2,混合搅拌,文火蒸发水分,得膏状混合物,加入蜂蜜10g,搅拌均匀,即可。
实施例4
实验动物:豚鼠,雌雄各半,SPF级,体重270-300g,合格检验证字:粤检证字第2010A068号,所有动物安静环境饲养,自由取食饮水,人工昼夜节律(12h-12h)。
试剂:石碳酸、生理盐水、乙醚
药物:
对照药:冰硼散(广西万通制药有限公司)
试验药:实施例1所得的药物,简称“低剂量组”
实施例2所得的药物,简称“中剂量组”
实施例3所得的药物,简称“高剂量组”
仪器:超净工作台、注射器、玻璃管、数码相机
取50只豚鼠复制口腔溃疡模型,用乙醚麻醉豚鼠,将一小棉球置于直经为5mm的玻璃管一端,使之与管口平齐;再将玻璃管放在90%石碳酸溶液中,使溶液浸透棉球;然后将玻璃管的棉球端置于豚鼠一侧颊黏膜上烧灼约60s,24~48h后观察,可见该区域有直径约5mm的白色损害,次日肉眼可见大鼠口唇边潮湿,流口水,颊黏膜处红肿,即造模成功。
将造模豚鼠随机均分为5组,按以下方法给药:低、中、高剂量组分别涂敷实施例1、实施例2、实施例3所得的药物,敷在豚鼠口腔溃疡处3min,厚度为2mm;冰硼散混悬液(用生理盐水配成0.25g/mL,涂敷厚度2mm,相当于0.5g/ml创面),敷在豚鼠口腔溃疡处3min。每天用药2次,连续7d。于第1,3,5d用数码相机摄下豚鼠口腔溃疡情况(焦距3cm,照相距2cm),使用BI一2000医学图像分析系统自动计算溃疡面积。于最后1次用药后2h,按评判标准评价豚鼠口腔溃疡程度。
试验结果如下:
对豚鼠口腔溃疡模型溃疡面积的影响。造模第1天,与空白组比较,模型组出现明显口腔溃疡(直径5±0.3mm),表明口腔溃疡模型复制成功,各给药组溃疡面积与模型组比较无显著性差异。与模型组比较,用药第3天、第5天、第7天,低剂量组、中剂量组、高剂量组和冰硼散组均可显著缩小口腔溃疡面积(P<o.01),见表l。
表1:
造模第1天,与空白组比较,模型组和各给药组局部均出现显著病理变化(P<0.01),表明口腔溃疡造模成功;模型组与各给药组溃疡局部症状无明显差异,分组均匀可比。与模型组比较,用药第3天,冰硼散组可显著减轻溃疡局部症状(P0.01);低剂量组、中剂量组、高剂量组均可明显减轻溃疡局部症状(P<0.05);用药第7天高剂量组和冰硼散组最明显减轻溃疡局部症状(P<0.05),见表2。
表2:
“0”无溃疡,口腔黏膜正常;“I”有溃疡,溃疡表面无明显假膜;“Ⅱ”溃疡表面有薄的一层黄色假膜,周围无水肿;“Ⅲ”溃疡表面假膜较厚,且周闹伴有炎性水肿;Ⅳ溃疡表面假膜厚,周围伴有明显炎性水肿。
与空白组比较,模型组口腔溃疡局部出现显著病理损伤(p<0.01);与模型组比较,低剂量组、中剂量组、高剂量组和冰硼散组均能显著减轻豚鼠口腔溃疡局部病理改变(P<0.01),见表3。
表3:
组别 | - | + | ++ | +++ | P |
空白组 | 10 | 0 | 0 | 0 | <0.01 |
模型组 | 0 | 1 | 2 | 7 | <0.01 |
低剂量组 | 5 | 3 | 2 | 1 | <0.01 |
中剂量组 | 6 | 3 | 1 | 0 | <0.01 |
高剂量组 | 8 | 2 | 0 | 0 | <0.01 |
冰硼散组 | 6 | 4 | 0 | 0 | <0.01 |
与模型组比较,P<O.O1;“一”口腔黏膜上皮完整,黏膜为鳞状上皮覆盖,黏膜下层为疏松的结缔组织,毛囊腺体下面为肌组织;“+”几腔黏膜溃疡缩小2/3,余1/3的溃疡面积被新生的肉芽组织所修复;“++”口腔黏膜溃疡缩小1/2,余1/2的溃疡面被新生的肉芽组织的所修复;“+++”口腔黏膜溃疡缩小1/3,或未缩小,余2/3的溃疡面被新生肉芽组织所修复。
Claims (1)
1.一种药物组合物在用于制备治疗口腔溃疡药物的用途,所述药物组合物为:
西洋参8g,鱼腥草20g,决明子15g,蜂蜜10g;其中,蜂蜜含水量为30%;
制备方法为:
a)西洋参8g磨粉,过120目,得粉末1,备用;
b)鱼腥草20g、决明子15g加入1500ml清水,浸泡20分钟后,煎煮1.5小时,得100ml汤剂,取上清液,过滤,得滤液2,备用;
c)粉末1加入滤液2,混合搅拌,文火蒸发水分,得膏状混合物,加入蜂蜜10g,搅拌均匀,即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510094348.6A CN104587034B (zh) | 2015-03-03 | 2015-03-03 | 一种药物组合物在用于制备治疗口腔溃疡的新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510094348.6A CN104587034B (zh) | 2015-03-03 | 2015-03-03 | 一种药物组合物在用于制备治疗口腔溃疡的新用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104587034A CN104587034A (zh) | 2015-05-06 |
CN104587034B true CN104587034B (zh) | 2017-05-17 |
Family
ID=53113305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510094348.6A Expired - Fee Related CN104587034B (zh) | 2015-03-03 | 2015-03-03 | 一种药物组合物在用于制备治疗口腔溃疡的新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104587034B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104922225A (zh) * | 2015-06-10 | 2015-09-23 | 周耀忠 | 中药组合物在制备治疗或预防口腔溃疡药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228597B (zh) * | 2011-06-13 | 2013-02-27 | 武汉理工大学 | 治疗口腔溃疡的药物以及制备的方法 |
CN103239731B (zh) * | 2013-04-26 | 2014-11-19 | 海南光宇生物科技有限公司 | 一种可食用的治疗口腔溃疡的口含贴片 |
CN103623261B (zh) * | 2013-11-22 | 2016-01-27 | 青岛市市立医院 | 一种治疗口腔溃疡的中药散剂及其制备方法 |
CN103784933B (zh) * | 2014-03-07 | 2016-04-06 | 王爱文 | 复发性口腔溃疡散 |
-
2015
- 2015-03-03 CN CN201510094348.6A patent/CN104587034B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN104587034A (zh) | 2015-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102579988A (zh) | 用于预防和治疗牙龈炎的中药、中草药牙粉及制备方法 | |
CN101518600B (zh) | 一种治疗细菌或真菌性皮肤病的中药组合物及其制备方法 | |
CN101422579B (zh) | 一种治疗口腔溃疡的中药制剂 | |
CN102000194B (zh) | 一种治疗中耳炎的中药组合物及其制备方法 | |
CN103432559B (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
CN102266474A (zh) | 银连解毒胶囊 | |
CN104324125B (zh) | 一种治疗慢性咽炎的中药组合物及其制备方法 | |
CN104258304A (zh) | 一种通经祛风活络消痛的药酒 | |
CN103230513A (zh) | 一种治疗急慢性鼻炎的中药组合剂及其制备方法 | |
CN101164600A (zh) | 一种治疗痤疮、青春痘的药物 | |
CN104587034B (zh) | 一种药物组合物在用于制备治疗口腔溃疡的新用途 | |
CN102631630A (zh) | 一种治疗食滞肠胃型结肠炎的中药制备方法 | |
CN102579607B (zh) | 一种治疗痤疮的中药组合物 | |
CN105343847A (zh) | 一种含有艾叶的治疗湿疹的中药组合物及其制备方法 | |
CN104998074A (zh) | 一种治疗胃病的中药及其制备方法 | |
CN104587035B (zh) | 一种治疗口腔溃疡的药物组合物及其制备方法 | |
CN103494924B (zh) | 一种治疗湿热郁结型痤疮的中药组合物 | |
CN102552772B (zh) | 一种治疗久咳肺虚的中药 | |
CN104721786A (zh) | 一种治疗妊娠肝内胆汁淤积症的中药制剂及其制备方法 | |
CN104622983A (zh) | 治疗直肠炎的中药组合物及其制备方法 | |
CN104840823A (zh) | 一种治疗中耳炎的中药制剂及制法 | |
CN104606406A (zh) | 一种外用预防变应性鼻炎的中药膏及其制备方法 | |
CN104721572B (zh) | 一种治疗慢性结肠炎的中药 | |
CN103385971A (zh) | 一种治疗痤疮的中药组合物 | |
CN103860844A (zh) | 一种治疗慢性结肠炎的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190827 Address after: 528000 First Floor of Two North Towers No. 115 Zhangcha Road, Chancheng District, Foshan City, Guangdong Province Patentee after: Foshan Chinese Medicine Hospital Limited Address before: 528000 5th Floor, No. 1 Pulan Road, Chancheng District, Foshan City, Guangdong Province Patentee before: Zhang Yuanqiang |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170517 Termination date: 20200303 |
|
CF01 | Termination of patent right due to non-payment of annual fee |